Prospective evaluation of seropositive occult hepatitis B viral infection in lymphoma patients receiving chemotherapy

Hong Kong Medical Journal

Volumn 17, Issue 5, 2011, Pages 376-380

  Cheung, W I ^a   Lin, S Y ^a   Leung, Vincent KS ^a   Fung, Kitty SC ^a   Lam, Y K ^a   Lo, F H ^a   Chau, T N ^a  

^a UNITED CHRISTIAN HOSPITAL   (Hong Kong)

Author keywords

Adjuvant; Chemotherapy; Cytotoxic; DNA; Hepatitis B virus; Lymphoma; Non Hodgkin; T lymphocytes; Viral

Indexed keywords

ALANINE AMINOTRANSFERASE; CYCLOPHOSPHAMIDE; ENTECAVIR; EPIRUBICIN; HEPATITIS B SURFACE ANTIBODY; HEPATITIS B SURFACE ANTIGEN; PREDNISOLONE; RITUXIMAB; VINCRISTINE; VIRUS DNA;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANTIBODY DETECTION; ANTIGEN DETECTION; ARTICLE; B CELL LYMPHOMA; BIOCHEMISTRY; CANCER CHEMOTHERAPY; CANCER STAGING; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE CARRIER; FEMALE; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; LARGE CELL LYMPHOMA; MALE; MALIGNANT B CELL LYMPHOMA; MICROBIAL KINETICS; NONHODGKIN LYMPHOMA; OCCULT BLOOD TEST; OCCULT HEPATITIS B INFECTION; REBOUND; VIRAL KINETICS; VIRUS LOAD; VIRUS REACTIVATION;

AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ANTIVIRAL AGENTS; CARRIER STATE; CYCLOPHOSPHAMIDE; DNA, VIRAL; EPIRUBICIN; FEMALE; GUANINE; HEPATITIS B; HEPATITIS B ANTIBODIES; HEPATITIS B CORE ANTIGENS; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VIRUS; HUMANS; LIVER FUNCTION TESTS; LYMPHOMA; MALE; MIDDLE AGED; PREDNISOLONE; PROSPECTIVE STUDIES; TIME FACTORS; VINCRISTINE; VIRAL LOAD;

EID: 83155165301     PISSN: 10242708     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (11)

1. Rehermann B, Ferrari C, Pasquinelli C, Chisari FV. The hepatitis B virus persists for decades after patients' recovery from acute viral hepatitis despite active maintenance of a cytotoxic T-lymphocyte response. Nat Med 1996;2:1104-8.
2. Raimondo G, Allain JP, Brunetto MR, et al. Statements from the Taormina expert meeting on occult hepatitis B virus infection. J Hepatol 2008;49:652-7.
3. Lok AS, Liang RH, Chiu EK, Wong KL, Chan TK, Todd D. Reactivation of hepatitis B virus replication in patients receiving cytotoxic therapy. Report of a prospective study. Gastroenterology 1991;100:182-8.
4. Hui CK, Cheung WW, Zhang HY, et al. Kinetics and risk of de novo hepatitis B infection in HBsAg-negative patients undergoing cytotoxic chemotherapy. Gastroenterology 2006;131:59-68.
5. Yeo W, Chan TC, Leung NW, et al. Hepatitis B virus reactivation in lymphoma patients with prior resolved hepatitis B undergoing anticancer therapy with or without rituximab. J Clin Oncol 2009;27:605-11.
6. Sarrecchia C, Cappelli A, Aiello P. HBV reactivation with fatal fulminating hepatitis during rituximab treatment in a subject negative for HBsAg and positive for HBsAb and HBcAb. J Infect Chemother 2005;11:189-91.
7. Law JK, Ho JK, Hoskins PJ, Erb SR, Steinbrecher UP, Yoshida EM. Fatal reactivation of hepatitis B post-chemotherapy for lymphoma in a hepatitis B surface antigen-negative, hepatitis B core antibody-positive patient: potential implications for future prophylaxis recommendations. Leuk Lymphoma 2005;46:1085-9.
8. Lok AS, McMahon BJ. Chronic hepatitis B: update 2009. Hepatology 2009;50:661-2.
9. Ho SK, Yam WC, Leung ET, et al. Rapid quantitation of hepatitis B virus DNA by real-time PCR using fluorescent hybridization probes. J Med Microbiol 2003;52:397-402.
10. Cheung WI, Chan HL, Leung VK, et al. Reactivation of hepatitis B virus infection with persistently negative HBsAg on three HBsAg assays in a lymphoma patient undergoing chemotherapy. J Clin Virol 2010;47:193-5.
11. European Association for the Study of the Liver. EASL Clinical Practice Guidelines: management of chronic hepatitis B. J Hepatol 2009;50:227-42.